Last reviewed · How we verify
Eptifibatide Injection
Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation by preventing fibrinogen binding to platelet receptors.
Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation by preventing fibrinogen binding to platelet receptors. Used for Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction), Percutaneous coronary intervention.
At a glance
| Generic name | Eptifibatide Injection |
|---|---|
| Sponsor | Ministry of Science and Technology of the People´s Republic of China |
| Drug class | Glycoprotein IIb/IIIa inhibitor |
| Target | Glycoprotein IIb/IIIa receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Eptifibatide is a cyclic heptapeptide that reversibly binds to the glycoprotein IIb/IIIa receptor on platelet surfaces, inhibiting the final common pathway of platelet aggregation. By blocking fibrinogen and von Willebrand factor from cross-linking platelets, it prevents thrombus formation. This antiplatelet effect is used during percutaneous coronary intervention to reduce ischemic complications.
Approved indications
- Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction)
- Percutaneous coronary intervention
Common side effects
- Bleeding
- Thrombocytopenia
- Hypotension
- Bradycardia
Key clinical trials
- Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke (EPOCH) (PHASE3)
- Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST) (PHASE2)
- A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks (PHASE2)
- Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: